title: Paclitaxel, bropirimine and linomide: effect on growth inhibition in a murine prostate cancer model by different growth regulatory mechanisms.
abstract: Paclitaxel, bropirimine and linomide therapy was evaluated in a murine prostate cancer model. All drugs were effective in impeding tumor growth but the mechanisms of action varied. Paclitaxel inhibited bcl-2 expression suggesting an apoptotic mechanism. Bropirimine, while inhibiting bcl-2 expression also significantly depressed tumor necrosis factor-alpha (TNF-alpha) expression. In the bropirimine treated group there was also a correlation between angiogenesis and cyclin D expression. Finally, linomide significantly decreased angiogenesis. Since the mechanism of action of these drugs differ, combining them at lower doses might maintain therapeutic efficacy while reducing toxicity.
authors.affiliation: Division of Cellular Biology, Hektoen Institute for Medical Research, Chicago, USA.
authors.forename: M
authors.initials: M
authors.lastname: Shaw
authors.forename: S
authors.initials: S
authors.lastname: Ratanawong
authors.forename: P
authors.initials: P
authors.lastname: Chou
authors.forename: V
authors.initials: V
authors.lastname: Ray
authors.forename: Y
authors.initials: Y
authors.lastname: Mirochnik
authors.forename: L
authors.initials: L
authors.lastname: Slobodskoy
authors.forename: M
authors.initials: M
authors.lastname: Rubenstein
authors.forename: P
authors.initials: P
authors.lastname: Guinan
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D003596:Cytosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D006912:Hydroxyquinolines / Q000494:pharmacology*; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008954:Models, Biological; D017239:Paclitaxel / Q000494:pharmacology*; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D051381:Rats; D011916:Rats, Inbred F344
chemical_list: D000970:Antineoplastic Agents; D006912:Hydroxyquinolines; D019253:Proto-Oncogene Proteins c-bcl-2; C045282:roquinimex; D003596:Cytosine; C033560:bropirimine; D017239:Paclitaxel